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Abstract Myoepithelial carcinoma of soft tissue (MEC) and
cellular extraskeletal myxoid chondrosarcoma (cEMC) share
striking similarities. In this paper, we compare ten MECs with
five cEMCs. MEC patients had an equal gender distribution.
The age range was 15–76 years (mean, 42 years). Tumours
were located on extremities, pelvic girdle, vulva and neck.
Follow-up, available for nine patients, ranged from 4 to
85 months (mean, 35 months). Five patients were alive with-
out evidence of disease, two were alive with disease and two
died 8 months after the initial diagnosis. cEMCs were from
three males and two females withan age range of37–82 years
(mean, 57 years); they presented in extremities, shoulder and
paravertebral/cervical. Follow-up, available for four patients,
ranged from 6 to 220 months (mean, 61 months). All patients
were alive, two with recurrences and/or metastases and two
without evidence of disease. Morphologically, the distinction
between these two entities was difficult since all cases
exhibited features typically seen in myoepithelial tumours.
Immunohistochemically, MECs expressed pan-keratin
(80 %), epithelial membrane antigen (EMA; 57 %), S100
(50 %), alpha-smooth muscle actin (ASMA; 75 %), calponin
(67 %) and p63 (25 %). S100 and EMA were expressed in
40 % of cEMC cases respectively with additional immunore-
activity for p63, ASMA and glial fibrillary acidic protein in
one case. Pan-keratin was negative in all neoplasms. NR4A3
rearrangement was present in four offour cEMCs and in none
of the MECs. In contrast, three of nine (33 %) MECs and four
of five (80 %) cEMCs showed an EWSR1 rearrangement. In
summary, MECs and cEMCs share clinical, morphological,
immunohistochemicaland geneticcharacteristics. The pathog-
nomic rearrangement of NR4A3 is a useful diagnostic feature
in identifying cEMCs.
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Myoepithelial tumours of the soft tissue were initially charac-
terised in a series by Kilpatrick et al. [1]. Later on, criteria for
malignancy were established and the clinicopathological fea-
tures expanded [2, 3]. Histologically, these tumours show the
same broad variation in morphology as seen in their salivary
gland counterparts [1–4].
Extraskeletal myxoid chondrosarcomas (EMCs) reveal a
cord- or lace-like arrangement of small round to spindle-
shaped cells with distinct eosinophilic cytoplasm distributed
in a prominent myxoid stroma. In cellular lesions (cEMCs),
amounting to one third of the cases, there is a greater morpho-
logical diversity [5–11]. Although the age range is broad for
both entities, the peak incidence for EMC is the sixth and for
MEC the fourth decade [2, 4, 12]. Furthermore, a significant
subset of malignant myoepithelial tumours or myoepithelial




in the deep soft tissue [2, 4, 12]. Whereas EMCs have a
protracted clinical course with a 10-year survival rate up to
88 % [5, 8, 14–16], MECs typically demonstrate aggressive
behaviour, particularly in the pediatric population [2, 3].
Whether or not also cEMCs have a worse prognosis remains
controversial [5–10].
Histologically, cEMC can be morphologically similar to
myoepithelial tumours but the latter have a broader immuno-
histochemical profile [2–4, 12]. Gene fusions involving
NR4A3 (nuclear receptor subfamily 4, group A, member 3)
located at 9q22 are characteristic for EMC and have never
been described in myoepithelial tumours. In contrast, both
tumour types harbour EWSR1 (Ewing sarcoma breakpoint
region 1; 22q12.2) rearrangement [3, 12, 17–25].
In this paper, we report on the morphological, immunohis-
tochemical and molecular overlap of MEC and cEMC.
Material and methods
We searched the surgical pathology and referral files of the
authors for the diagnoses myoepithelial tumours of soft
tissueandEMC.Slideswerereviewedandthediagnoseswere
based on criteria according to the recent WHO classification
[26]. Myoepithelial tumours with moderate to severe nuclear
atypia (vesicular or coarse chromatin, prominent, often large
nucleoli, or nuclear pleomorphism) and EMCs with cellular
features were included in our study. Clinical details and
follow-up were obtained from the referring pathologists (see
“Acknowledgement”). Cases 8 and 10 were published earlier
[3, 27, 28].
In all cases, the tissue was fixed in 4 % buffered formalin,
routinely processed and embedded in paraffin; 2–4-μm-thick
sections were stained with hematoxylin and eosin. Immuno-
histochemical methods consisted of the labelled Streptavidin
Biotin technique using commercially available antibodies as
listed in Table 1. Appropriate positive and negative controls
were used throughout.
Fluorescence in situ hybridisation analysis
Fluorescence in situ hybridisation (FISH) was performed as
described earlier. For EWSR1, a directly FITC/Rhodamine-
labelled break apart-probe (Abbott, Bergisch Gladbach,
Germany) was used [29]. FISH probes to detect a NR4A3
rearrangement (break apart probe) were generated in-house.
BAC clones RP11-624K13 (centromeric), RP11-412F16
(centromeric), RP11-121L12 (telomeric) and RP11-467B11
(telomeric) were obtained from the BACPAC Resources
Center(Oakland, CA). Clones were either labelled with biotin
or digoxigenin using a nick translation kit, according to man-
ufacturer’s instructions (Roche, Basel, Switzerland). Copy
numbers of chromosome 9 were assessed using a centromere
probe (CEP9). A negative control was used for each tumour.
A case was considered having a break when at least 10 of 50
counted tumour cells (20 %) showed separation of a red and
green signal.
Reverse transcription polymerase chain reaction
RNA was isolated from formalin-fixed, paraffin-embedded
material by proteinase K digestion, followed by phenol/
chloroform extraction and n-propanol precipitation. cDNA
synthesis was performed in a 24-μl reaction containing 1 μg
Table 1 Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO, Glostrup, Denmark
EMA Mc5 1:400 BioGenex, San Ramon, USA
CD34 HPCA-1 1:100 BD Biosciences, San Jose,
USA
Pan-cytokeratin MNF116 1:500 DAKO, Glostrup, Denmark
Pan-cytokeratin AE1/3 1:50 DAKO, Glostrup, Denmark
S-100 protein polyclonal 1:2000 DAKO, Glostrup, Denmark
P63 4A4 1:5000 Thermo Fisher Scientific, USA
GFAP GA-5 1:200 DCS, Hamburg, Germany
Calponin CALP 1:400 DAKO, Glostrup, Denmark
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dNTPs (Invitrogen) and heated at 65°C for 5 min. Next, 2 μl
of RNasin (Promega), 8 μl of ×5 first-strand buffer
(Invitrogen), 4 μl of 0.1 M DTT (Invitrogen) and 2 μl
of Superscript II (Invitrogen) were added and the sample
was heated accordingly: 20°C for 10 min, 42°C for
60 min and 95°C for 3 min.
For EMC, most potential translocation-specific EWSR1-
NR4A3andTAF15-NR4A3fusionproductsweredetectedusing
primers targeting EWSR1 (exon 7: TCCTACAGCCAAGCTC
CAAGTC and exon 11: GACTCTAGATGATCTGGCAGAC,
RefSeq: NM_005243.3), TAF15 (TAF15 RNA polymerase II)
(exon 6: AGCAGTCAAATTATGATCAGCAGC, RefSeq:




Clinical details are summarised in Table 2. The MEC cohort
consisted of five males and five females with an age range of
15–76 years (mean, 42 years). The tumours were located on
the extremities (n04) with one case each on the thigh, calf,
forearmandhand.Othersiteswerevulva(n02),gluteal(n01),
sacral (n01) and the neck region (n01). In one case, the exact
anatomic site was not known. Seven MECs were situated in
the deep soft tissue and two subcutaneous. One superficially
located tumour of the vulva showed exophytic growth. All
patients underwent surgical treatment. Complete resection was
reached in seven cases and marginal excision in one case.
Tumour-positive margins were reported in two cases. Follow-
up, available for nine patients, ranged from 4 to 85 months
(mean, 35 months). Five patients were alive without evidence
of disease at 12, 34, 39, 60 and 70 months, respectively. Two
patients were alive with disease 4 and 85 months after the
initial diagnosis, the latter with a second local recurrence. Two
patients died of disease 8 months after the initial diagnosis.
Case 10 was the first local recurrence on the hand with sec-
ondary bone involvement. Three patients presented with lung
metastases. Involvement of regional lymph nodes was addi-
tionally observed in two of them, and one patient had bone
metastases.
The five cases of EMC were from three males and two
females with an age range of 37–82 years (mean, 57 years).
Twolesions were locatedinthe deep soft tissue of the thighand
one in the subcutis and soft tissue of the shoulder. One tumour
each arose at the ankle and the paravertebral/cervical region.
All patients but one (n04) underwent resection. Tumour
free resection margins were reported in three cases (wide
margins in two cases and marginal resection in one case). In
Case 14, the resection status was not known. Follow-up,
available for four patients, ranged from 6 to 220 months
Table 2 Clinical data
Case No Sex/Age Primary Site Size (cm) Therapy Follow-up (months) Rec (Met)
MEC
1 F/36 years na/sc 4.5 R0 NA
2 F/21 years Thigh/deep 5.0 R0 70, NER
3 F/53 years Vulva/exophytic 3.5 R0 60, NER
4 F/75 years Vulva 3.5 R0 34, NER
5 M/36 years Forearm/deep 10 R0 8, DOD Lung
6 F/15 years Neck/deep 4 R2 85, AWD 2 rec
7 M/15 years Sacral/deep 5 R0 39, NER
8 M/17 years Calf/deep 12 R0, perf,amp 8, DOD Bone, lung, LN
9 M/71 years Buttock/sc 15 R1 4, AWD Lung, LN
10 M/76 years Hand/deep, bone invasion 4.5 RM 12, NER 1 rec
EMC
11 M/61 years Thigh/deep 8.1 R0 12, NER
12 M/58 years Thigh/deep 10 R0 6, NER
13 F/37 years Shoulder/sc, deep 15 NT 6, AWD LN
14 M/82 years Paravertebral/cervical NA RX NA
15 F/46 years Ankle 1 RM 220, AWD 4 rec, lung
Mos months, Rec recurrence, Met metastases, Sc subcutis, LN lymph node, NER no evidence of recurrence, AWD alive with disease, DOD death of
disease, NA not available, NT no treatment, Perf limb perfusion, Amp amputation, R0 complete resection, RM marginal resection, R1 resection with
histological positive margins, R2 resection with macroscopically positive margins, RX resection with unknown margins
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15 was the 4th recurrence of a tumour with primarily classical
morphological features. This patient had also pulmonary
spread. Another patient was known with regional lymph node
involvement (Case 13).
Pathological findings
Grossly, the neoplasms were described as white or yellowish
nodules, solid, gelatinous and also cystic in appearance.
Haemorrhage and necrosis was seen in some of the lesions.
ThesizerangeforMECswas3.5to15cm(mean,6.7cm)and
for EMCs 1 to 15 cm (mean, 8.5 cm). In one EMC, the size
was unknown.
Histologically, most cases demonstrated a (multi)nodular
configuration with expansive margins and an incomplete
pseudo-capsule. Infiltrative margins were focally seen. MECs
showed in most of the cases varying growth patterns such as
trabecular, reticular, nested and solid. A pure trabecular pat-
tern was seen in two cases. Six tumours were composed of
different cell types, including spindle, epithelioid, plasmacy-
toidand/orclearcells.Roundcellmorphologyassociatedwith
clear cell features was observed in two cases and a pure
epithelioid phenotype in two other cases (Fig. 1). Osteoclast-
like giant cells were scattered in Cases 1 and 4. All cases
exhibited moderate to severe nuclear atypia with vesicular or
coarse chromatin (Fig. 2). Prominent nucleoli were conspicu-
ous in seven cases. Mitoses ranged from one to six per ten
HPF. The matrix was (chondro)myxoid in eight cases with
pseudocystic changes in two cases. Five tumours showed
stromal hyalinisation. Areas of haemorrhage and tumour
necrosis were observed in one and two cases, respectively.
All EMC cases had focally classical features with strands
andcordsof small,uniform roundtospindle-shapedcellsset in
a prominent myxoid matrix. There were round to oval nuclei
and limited deeply eosinophilic cytoplasm. The tumour nod-
ules, separated by fibrous septa, often showed peripheral cell
condensation. In the cellular areas, sheets and nests of tumour
cells were present. A trabecular and reticular-cystic pattern as
well as loosely arranged cells occurred variably. The lesional
cells were epithelioid and/or spindle shaped and slightly pleo-
morphic (Figs. 3 and 4). Case 13 showed increased pleomor-
phism, cytoplasmic vacuoles, multinucleated giant cells and
prominent necrosis. In two cases, larger nuclei and prominent
nucleoli were seen (Cases 11 and 12). Rhabdoid cytology was
observedinCase12.Forallcases,themitoticactivitywasvery
low and did not exceed one mitosis/ten HPF. In the cellular
areas, the myxoid matrix was scant or even absent.
Immunohistochemically, eight of ten (80 %) myoepithelial
carcinomas were, at least focally, positive for pan-cytokeratin
and four of seven (57 %) for epithelial membrane antigen
(EMA). The two cases negative for pan-cytokeratin expressed
Fig. 1 This case of MEC showed a reticular and cord-like pattern of
epithelioid cells set in a prominent myxoid matrix (Case 5)
Fig. 2 Note the nuclear pleomorphism, more often seen in MEC
(Case 3)
Fig. 3 Monomorphic epithelioid and spindle-shaped cells in a cellular
EMC (Case 11)
624 Virchows Arch (2012) 460:621–628EMA. Two of eight cases showed nuclear immunoreactivity
for p63 (25 %). Alpha-smooth muscle actin (ASMA) was
detected in six ofeight(75 %) andcalponin in fourof six cases
(67 %). A focal expression of S100 was seen in five of ten
cases (50 %). Glial fibrillary acidic protein (GFAP), in four
cases performed,wasnegativein allfour. In cEMCs, S100 and
EMAwere each expressed in two of five cases (40 %). One of
the mentionedS100-positivecases(Case 11)showed abroader
pattern of marker expression with additional immunoreactivity
for (Fig. 5) p63 and focally for ASMA and GFAP. Pan-
cytokeratin was negative in all neoplasms (Table 3).
FISH and RT-PCR analysis
In three of nine (33 %) MECs, a EWSR1 rearrangement was
observed by FISH. One case failed for analysis due to poor
hybridisation. No tumour showed a NR4A3 rearrangement.
Aberrationsofchromosome9wereseenintwoinstances.One
of them harboured a polysomy and one a heterozygous dele-
tion. All EMCs successfully tested (four of five) exhibited a
NR4A3 rearrangement (Fig. 6). One case failed for reverse
transcription polymerase chain reaction (RT-PCR) and
NR4A3-FISH. Three cases showed a EWSR1 rearrangement
by FISH. In one of them, a fusion of TAF15-NR4A3 was
additionally detected by RT-PCR. In Case 15, NR4A3 was
rearranged (by FISH) but a fusion with EWSR1 or TAF15 was




by Stout and Gorman in 1959 in a series of cutaneous lesions
[30]. In the largest series to date, moderate to severe atypia
(vesicular or coarse chromatin, prominent, often large nucleoli
or nuclear pleomorphism) was determined as indicating malig-
nancy [2]. The wide morphological and immunohistochemical
diversity, presumably a result of the plasticity of myoepithelial
cells, is the cause of the many differential diagnoses, which
include most importantly the cellular variant of extraskeletal
myxoid chondrosarcoma, furthermore atypical/malignant
ossifying fibromyxoid tumour, undifferentiated carcinoma,
Fig. 4 Solid and reticular arrangement of slightly polymorphic epithe-
loid cells in a cellular EMC
Table 3 Immunohistochemistry
Case Pan-CK EMA p63 ASMA S100 GFAP Calponin
MEC
1 − + − f+ − nd +
2+ n d − f+ f+ − f+
3f + n d − f+ − nd f +
4 − + − f+ −− nd
5f + − nd f+ − nd nd
6+ n d ++ − nd nd
7+ + −− f+ −−
8+ − nd nd + − +
9+ −−− f+ nd −
10 + + + nd f+ nd nd
8/10 4/7 2/8 6/8 5/10 0/4 4/6
80 % 57 % 25 % 75 % 50 % 0 % 67 %
EMC
11 −− +f +f + f +n d
12 −− − − f+ − nd
13 − f+ nd −− − nd
14 − −−− −− nd
15 − f+ −− −− nd
0/5 2/5 1/4 1/5 2/5 1/5
0 % 40 % 25 % 20 % 40 % 20 %
f focally, nd not done
Fig. 5 p63 was positive in one of the cellular EMC cases (Case 11)
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cases with round cell morphology, Ewing sarcoma, myxoid/
round cell liposarcoma and poorly differentiated synovial
sarcoma are to be considered, at least in small samples [2–4].
The occurrence of myoepithelial tumors at different sites
possibly reflects an aberrant gene expression pattern during
oncogenesis rather than an origin from a specific cell lineage
[3].ThisissupportedbytheevidenceofEWSR1rearrangement
in a subset of benign and malignant myoepithelial tumours of
skin, soft tissue, bone and visceral locations (lung) [25, 31].
The hitherto identified fusion genes are POU5F1, PBX1
and ZNF444 [23–25]. Other more heterogenous genetic
changes are also identified including recurrent aberrations
of chromosome 9 [27, 32–34]. Recently, a pleomorphic
adenoma gene 1 (PLAG1) rearrangement was discovered
in a subset of benign mixed tumours of skin and soft tissues
(with well-formed ducts). It seems that this genetic abnormal-
ity excludes EWSR1 rearrangement [35]. Whether malignant
myoepithelial/mixedtumourspossesssimilarfeaturesremains
unresolved as yet.
When Enzinger designated extraskeletal myxoid chondro-
sarcomaasadistinctentityhealreadymentionedaresemblance
with salivary gland type, mixed tumours of deep fascial region
of thigh with reference to the report by Dutra in 1960 [5, 36].
Classical cases of EMC have a typical histomorphology with
uniform small round to spindle-shaped cells with deeply eosin-
ophilic cytoplasm. The cells are arranged in a delicate network
set in a copious myxoid stroma. Cellular variants, represent-
ing approximately one third of the cases, show greater
morphologic heterogeneity, often resembling myoepithelial
tumours [2, 4, 5, 8, 10, 11, 25, 33, 37, 38].
Both tumour types share features such as lobular/multi-
nodular architecture, variable amounts of myxoid stroma and
a reticular growth pattern. The stromal component in cellular
areas can be poor or even absent. The cells are variably
epithelioid, round and spindle shaped. Rhabdoid cytology
mayalsobepresentinboth.Unlikemyoepithelialcarcinomas,
moderate to severe nuclear atypia is much less common in
cEMCand cantherefore beahelpfuldiscriminatingsign.This
was also a finding in our series. Ductular structures and
metaplastic cartilage or bone, present in not more than 20 %
of soft tissue myoepithelial tumours, are not a feature of EMC
[2–8, 10, 38–41]. None of our MECs demonstrated one of
these characteristics.
Immunohistochemically, soft tissue myoepithelial tumours
usually show expression of keratins (90–95 %), EMA (60 %),
S100 (85 %), GFAP (50 %), calponin (90 %), SMA (40 %)
and p63 (40 %) [4, 42]. In contrast, EMCs are often focally,
positive for S100. GFAP, EMA, ASMA and keratins are
expressed in a minority of cases, mostly with a focal staining
pattern [2, 4, 6–8, 10, 12, 33, 38–41]. In our series, pankeratin
was the most distinctive marker expressed in 80 % of MECs
but in none of the EMCs. Although our series is small, this
result mirrors those by others [8]. p63, labelling myoepithelial
cells at different sites, is positive in circa 40 % of MECs and
can be exceptionally positive in EMCs as we found in one of
our cases [42].
Loss of SMARCB1/INI1 is also an overlapping feature of
the describedentitiesandhasbeendemonstratedina subsetof
cases. Whereas underlying genetic alterations (homozygous
deletion and frameshift mutation) have been detected in some
EMCs, genetic aberrations have not been investigated in
Table 4 Molecular analyses (FISH*, RT-PCR)










5 − nd −−
6+ −
7 −−




11 + nd + −
12 nd nd − +
13 + + × ×
14 + × × ×
15 nd + −−
“+” rearrangement, “−“ no rearrangement, “×” analysis failed, nd not
done
Fig. 6 NR4A3 rearrangement by FISH showing break-apart signal.
This was observed in all EMC cases successfully tested
626 Virchows Arch (2012) 460:621–628myoepithelial carcinomas as yet [3, 39]. Interestingly, the
SMARCB1/INI1-negative EMC cases lack a typical major
fusion gene transcript [39]. This raises the question whether
these cases are more related to myoepithelial tumours.
EMCsaredefinedbyspecificreciprocaltranslocations,involv-
ing the pathognomonic NR4A3. The described fusion partners
are,indecreasingfrequency,EWSR1, TAF15, TCF12 andTGF
[17–22].
By RT-PCR or FISH analysis, NR4A3 rearrangement was
found in all of our successfully tested EMCs. In one case, we
detectedbesidesaTAF15-NR4A3fusionanadditionalEWSR1
rearrangement which is in line with another reported more
complex rearranged case [43]. Furthermore, 33 % of our
myoepithelial carcinomas showed EWSR1 rearrangement,
consistent with the results by Antonescu et al. [25]. We did
not find NR4A3 rearrangement in any of the myoepithelial
carcinomas, but as previously reported, changes of chromo-
some 9 as a recurrent aberration were seen in two of our cases
[27, 34].
In summary, myoepithelial carcinoma of soft tissue and
cellular extraskeletal myxoid chondrosarcoma share clinical,
morphological, immunohistochemical and genetic similarities.
The pathognomic rearrangement of NR4A3 and the general
lack of keratin expression identify most cases of cEMC. The
seemingly poorer outcome especially in young patients with
myoepithelial carcinomas and possible different treatment
options make discrimination between these different entities
necessary.
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